title: Cell-mediated immunity against HGP-30, a group-specific peptide of HIV p17 in individuals infected with the AIDS virus.
abstract: HGP-30, the synthetic peptide analogue and active component in an HIV-1 (human immunodeficiency virus, type 1) p 17 core-based experimental vaccine, has previously been shown to induce cytotoxic and helper T-lymphocyte responses. In order to further define the T-helper cell responses which are known to play a role in enhancing the immunological response to foreign antigens, we studied the response of individuals infected with HIV to HGP-30 at various stages of disease progression. We have investigated the proliferative cellular response of peripheral blood mononuclear cells (PBMCs) derived from individuals infected with HIV-1 to HGP-30. We have found a PBMC proliferative response to HGP-30 in 40% of the healthy seroconverted patients, in 35% of the CDC stage III patients and in 18% of the CDC stage IV patients. There was no correlation between the proliferative response to HGP-30 and other antigens such as HIV-like proteins or tetanus toxoid not to CD4 cell count. HLA-DR typing revealed the possible presentation of HGP-30 by several different class II molecules. Since these class II molecules occur frequently in the general population, HGP-30 appears to contain broadly reactive epitopes and thus is not restricted as are many peptide vaccines. Due to its broad reactivity and extreme conservation in many HIV-1 strains. HGP-30 is one of the promising candidates for inclusion as a subunit vaccine against HIV-1.
authors.affiliation: Université Pierre et Marie Curie, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Willer
authors.forename: A
authors.initials: A
authors.lastname: Achour
authors.forename: J P
authors.initials: JP
authors.lastname: Mbika
authors.forename: K
authors.initials: K
authors.lastname: Laaroubi
authors.forename: A
authors.initials: A
authors.lastname: Lachgar
authors.forename: A
authors.initials: A
authors.lastname: Nihrane
authors.forename: O
authors.initials: O
authors.lastname: Picard
authors.forename: P H
authors.initials: PH
authors.lastname: Naylor
authors.forename: P S
authors.initials: PS
authors.lastname: Sarin
authors.forename: A L
authors.initials: AL
authors.lastname: Goldstein
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology*; D015704:CD4 Antigens / Q000276:immunology; D005802:Genes, MHC Class II / Q000276:immunology; D015488:HIV Antigens / Q000494:pharmacology*; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D010455:Peptides / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000276:immunology; D013745:Tetanus Toxoid / Q000276:immunology; D054301:gag Gene Products, Human Immunodeficiency Virus
chemical_list: D015704:CD4 Antigens; C052407:HGP-30 peptide, Human immunodeficiency virus-1; D015488:HIV Antigens; D010455:Peptides; D013745:Tetanus Toxoid; D054301:gag Gene Products, Human Immunodeficiency Virus